Lexicon To Present At The BIO CEO & Investor Conference

           Lexicon To Present At The BIO CEO & Investor Conference

PR Newswire

THE WOODLANDS, Texas, Feb. 6, 2013

THE WOODLANDS, Texas, Feb. 6, 2013 /PRNewswire/ --Lexicon Pharmaceuticals,
Inc. (Nasdaq: LXRX) announced today that Arthur Sands, M.D., Ph.D., President
and Chief Executive Officer, will present at the Bio CEO & Investor Conference
on Monday, February 11, at 11:00 AM EST in New York City. Dr. Sands will
provide an overview of Lexicon's clinical development programs and milestones.

A webcast of the presentation will be available through Lexicon´s website at
www.lexpharma.com. An archived version of the presentation will be available
at www.lexpharma.com until March 11, 2013.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough
treatments for human disease. Lexicon currently has four drug programs in
mid-stage development for diabetes, irritable bowel syndrome, carcinoid
syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's
research team. Lexicon has used its proprietary gene knockout technology to
identify more than 100 promising drug targets. Lexicon has focused drug
discovery efforts on these biologically-validated targets to create its
extensive pipeline of clinical and preclinical programs. For additional
information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements
relating to Lexicon's growth and future operating results, discovery and
development of products, strategic alliances and intellectual property, as
well as other matters that are not historical facts or information. All
forward-looking statements are based on management's current assumptions and
expectations and involve risks, uncertainties and other important factors,
specifically including those relating to Lexicon's ability to successfully
conduct preclinical and clinical development of its potential drug candidates,
advance additional candidates into preclinical and clinical development,
obtain necessary regulatory approvals, achieve its operational objectives,
obtain patent protection for its discoveries and establish strategic
alliances, as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial value of its
drug candidates, that may cause Lexicon's actual results to be materially
different from any future results expressed or implied by such forward-looking
statements. Information identifying such important factors is contained under
"Risk Factors" in Lexicon's annual report on Form 10-K for the year ended
December 31, 2011, as filed with the Securities and Exchange Commission.
Lexicon undertakes no obligation to update or revise any such forward-looking
statements, whether as a result of new information, future events or

SOURCE Lexicon Pharmaceuticals, Inc.

Website: http://www.lexpharma.com
Contact: Alex Abuin, Ph.D., Vice President, Communications and Alliance
Management, +1-281-863-3213, aabuin@lexpharma.com
Press spacebar to pause and continue. Press esc to stop.